<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Amyotrophic Lateral Sclerosis - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Amyotrophic Lateral Sclerosis</span>
        </nav>

        <header class="page-header">
            <h1>Amyotrophic Lateral Sclerosis</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0004976" target="_blank">
                        MONDO:0004976
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Motor Neuron Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neurodegenerative Disease</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Familial ALS</div>
                
                <div class="item-desc">Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Sporadic ALS</div>
                
                <div class="item-desc">Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Bulbar-onset ALS</div>
                
                <div class="item-desc">ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Limb-onset ALS</div>
                
                <div class="item-desc">ALS beginning with limb weakness, the most common presentation.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Motor Neuron Degeneration</div>
                
                <div class="item-desc">Progressive death of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord leads to denervation of skeletal muscles. The loss of upper motor neurons causes spasticity and hyperreflexia, while lower motor neuron loss results in muscle weakness, atrophy, and fasciculations.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        motor neuron
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38521060" target="_blank">PMID:38521060</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) share many clinical, pathological, and genetic features"</div>
                
                
                <div class="evidence-explanation">Single-cell analysis confirms motor neuron vulnerability in ALS and identifies vulnerable populations in cortical layer 5.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TDP-43 Proteinopathy</div>
                
                <div class="item-desc">Cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43) is found in approximately 97% of ALS cases. TDP-43 normally functions in RNA processing but becomes mislocalized from the nucleus to cytoplasmic inclusions, leading to both loss of nuclear function and toxic gain of function. This impairs RNA splicing including STMN2.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">RNA splicing</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16736722" target="_blank">PMID:16736722</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"the most common tau negative ubiquitin positive amyotrophic lateral sclerosis (ALS) type inclusions"</div>
                
                
                <div class="evidence-explanation">Review confirms ubiquitin-positive inclusions as a common pathological feature in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">C9orf72 Repeat Expansion Toxicity</div>
                
                <div class="item-desc">Hexanucleotide (GGGGCC) repeat expansion in C9orf72 is the most common genetic cause of ALS, accounting for 40% of familial and 5-10% of sporadic cases. The expansion leads to RNA foci formation, dipeptide repeat protein aggregation, and haploinsufficiency.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21944778" target="_blank">PMID:21944778</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%). The repeat expansion leads to the loss of one alternatively spliced C9ORF72 transcript and to formation of nuclear RNA foci,..."</div>
                
                
                <div class="evidence-explanation">Original discovery paper establishing C9orf72 repeat expansion as a major cause of both FTD and ALS with dual mechanisms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Glutamate Excitotoxicity</div>
                
                <div class="item-desc">Impaired glutamate clearance by astrocytes leads to excessive glutamate accumulation in the synaptic cleft, causing prolonged activation of glutamate receptors on motor neurons. This results in calcium overload and subsequent neuronal death.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000127" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">neurotransmitter transport</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8302340" target="_blank">PMID:8302340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis."</div>
                
                
                <div class="evidence-explanation">Trial of riluzole, an antiglutamate agent, supports role of glutamate excitotoxicity in ALS pathogenesis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress</div>
                
                <div class="item-desc">Motor neurons are particularly vulnerable to oxidative damage due to high metabolic demands. Mutations in SOD1, which encodes superoxide dismutase 1, lead to misfolded protein aggregation and increased oxidative stress contributing to neuronal death.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">response to oxidative stress</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8446170" target="_blank">PMID:8446170</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion"</div>
                
                
                <div class="evidence-explanation">Discovery of SOD1 mutations in familial ALS implicates oxidative stress in disease pathogenesis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neuroinflammation</div>
                
                <div class="item-desc">Activated microglia and astrocytes contribute to motor neuron death through the release of pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic factors. This non-cell-autonomous mechanism amplifies neurodegeneration.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        microglial cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000127" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34440810" target="_blank">PMID:34440810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In the archetypical neurodegenerative disorder amyotrophic lateral sclerosis (ALS), the recruitment of T-cells is well known"</div>
                
                
                <div class="evidence-explanation">Review confirms immune cell involvement in ALS pathophysiology with T-cell recruitment to affected areas.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Axonal Transport Dysfunction</div>
                
                <div class="item-desc">Impaired axonal transport leads to accumulation of organelles and proteins in motor neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">anterograde axonal transport</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired Autophagy</div>
                
                <div class="item-desc">Defects in autophagy and protein quality control pathways lead to accumulation of misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">autophagy</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Muscle Weakness
                    
                    <span class="phenotype-freq">OBLIGATE</span>
                    
                    
                    <span class="phenotype-category">Neuromuscular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001324" target="_blank">
                            HP:0001324
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31871139" target="_blank">PMID:31871139</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"motor neuron disease (MND)"</div>
                
                
                <div class="evidence-explanation">Study of motor neuron disease patients confirms muscle weakness as a defining feature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fasciculations
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neuromuscular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002380" target="_blank">
                            HP:0002380
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Spasticity
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001257" target="_blank">
                            HP:0001257
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hyperreflexia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001347" target="_blank">
                            HP:0001347
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dysarthria
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001260" target="_blank">
                            HP:0001260
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dysphagia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002015" target="_blank">
                            HP:0002015
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Respiratory Insufficiency
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002747" target="_blank">
                            HP:0002747
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Generalized Amyotrophy
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neuromuscular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0003700" target="_blank">
                            HP:0003700
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    C9orf72 Repeat Expansion
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21944778" target="_blank">PMID:21944778</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%)"</div>
                
                
                <div class="evidence-explanation">Original discovery paper establishing C9orf72 as the most common genetic cause of familial ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SOD1 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8446170" target="_blank">PMID:8446170</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We identified 11 different SOD1 missense mutations in 13 different FALS families."</div>
                
                
                <div class="evidence-explanation">Original discovery paper identifying SOD1 mutations as a cause of familial ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TARDBP Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    FUS Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NEK1 Variants
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Susceptibility)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27455347" target="_blank">PMID:27455347</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity."</div>
                
                
                <div class="evidence-explanation">Large-scale genetic study identifying NEK1 variants as risk factors for ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Riluzole
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8302340" target="_blank">PMID:8302340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset."</div>
                
                
                <div class="evidence-explanation">Landmark trial demonstrating riluzole&#39;s survival benefit in ALS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Edaravone
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28522181" target="_blank">PMID:28522181</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo."</div>
                
                
                <div class="evidence-explanation">Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Tofersen
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32640130" target="_blank">PMID:32640130</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks."</div>
                
                
                <div class="evidence-explanation">Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Non-invasive Ventilation
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000506" target="_blank">
                            MAXO:0000506
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.
</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Physical Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.
</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Speech Therapy
                    
                </div>
                
                <div class="item-desc">Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.
</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Percutaneous Endoscopic Gastrostomy
                    
                </div>
                
                <div class="item-desc">Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.
</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Multidisciplinary Care
                    
                </div>
                
                <div class="item-desc">Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.
</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Heavy Metal Exposure</div>
                
                <div class="item-desc">Occupational exposure to lead, mercury, and other heavy metals has been associated with increased ALS risk.</div>
                
                
                
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Pesticide Exposure</div>
                
                <div class="item-desc">Agricultural pesticide exposure has been linked to increased ALS incidence in epidemiological studies.</div>
                
                
                
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Military Service</div>
                
                <div class="item-desc">Veterans have approximately twice the risk of developing ALS compared to the general population, possibly related to environmental exposures.</div>
                
                
                
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Smoking</div>
                
                <div class="item-desc">Cigarette smoking is a confirmed risk factor for ALS, particularly in women.</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Neurofilament Light Chain (NfL)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Phosphorylated Neurofilament Heavy Chain (pNfH)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: CSF and serum biomarker of axonal injury</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Amyotrophic Lateral Sclerosis
category: Complex
description: &gt;
  Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig&#39;s disease, is a progressive
  neurodegenerative disorder characterized by the selective death of upper and lower motor
  neurons in the brain, brainstem, and spinal cord. This leads to progressive muscle weakness,
  atrophy, spasticity, and ultimately respiratory failure. ALS typically presents in adulthood
  with a median survival of 3-5 years from symptom onset. Approximately 5-10% of cases are
  familial, with the remainder being sporadic. A hallmark feature is TDP-43 proteinopathy,
  present in approximately 97% of cases.
disease_term:
  preferred_term: amyotrophic lateral sclerosis
  term:
    id: MONDO:0004976
    label: amyotrophic lateral sclerosis
parents:
  - Motor Neuron Disease
  - Neurodegenerative Disease
has_subtypes:
  - name: Familial ALS
    description: Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS.
  - name: Sporadic ALS
    description: Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology.
  - name: Bulbar-onset ALS
    description: ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement.
  - name: Limb-onset ALS
    description: ALS beginning with limb weakness, the most common presentation.
pathophysiology:
  - name: Motor Neuron Degeneration
    description: &gt;
      Progressive death of upper motor neurons in the motor cortex and lower motor neurons
      in the brainstem and spinal cord leads to denervation of skeletal muscles. The loss of
      upper motor neurons causes spasticity and hyperreflexia, while lower motor neuron loss
      results in muscle weakness, atrophy, and fasciculations.
    cell_types:
      - preferred_term: motor neuron
        term:
          id: CL:0000100
          label: motor neuron
    evidence:
      - reference: PMID:38521060
        supports: SUPPORT
        snippet: &#34;Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) share many clinical, pathological, and genetic features&#34;
        explanation: Single-cell analysis confirms motor neuron vulnerability in ALS and identifies vulnerable populations in cortical layer 5.
  - name: TDP-43 Proteinopathy
    description: &gt;
      Cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43) is found in approximately
      97% of ALS cases. TDP-43 normally functions in RNA processing but becomes mislocalized
      from the nucleus to cytoplasmic inclusions, leading to both loss of nuclear function
      and toxic gain of function. This impairs RNA splicing including STMN2.
    biological_processes:
      - preferred_term: RNA splicing
        term:
          id: GO:0000375
          label: RNA splicing, via transesterification reactions
    evidence:
      - reference: PMID:16736722
        supports: SUPPORT
        snippet: &#34;the most common tau negative ubiquitin positive amyotrophic lateral sclerosis (ALS) type inclusions&#34;
        explanation: Review confirms ubiquitin-positive inclusions as a common pathological feature in ALS.
  - name: C9orf72 Repeat Expansion Toxicity
    description: &gt;
      Hexanucleotide (GGGGCC) repeat expansion in C9orf72 is the most common genetic cause
      of ALS, accounting for 40% of familial and 5-10% of sporadic cases. The expansion
      leads to RNA foci formation, dipeptide repeat protein aggregation, and haploinsufficiency.
    evidence:
      - reference: PMID:21944778
        supports: SUPPORT
        snippet: &#34;Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%). The repeat expansion leads to the loss of one alternatively spliced C9ORF72 transcript and to formation of nuclear RNA foci, suggesting multiple disease mechanisms.&#34;
        explanation: Original discovery paper establishing C9orf72 repeat expansion as a major cause of both FTD and ALS with dual mechanisms.
  - name: Glutamate Excitotoxicity
    description: &gt;
      Impaired glutamate clearance by astrocytes leads to excessive glutamate accumulation
      in the synaptic cleft, causing prolonged activation of glutamate receptors on motor
      neurons. This results in calcium overload and subsequent neuronal death.
    cell_types:
      - preferred_term: astrocyte
        term:
          id: CL:0000127
          label: astrocyte
    biological_processes:
      - preferred_term: neurotransmitter transport
        term:
          id: GO:0006836
          label: neurotransmitter transport
    evidence:
      - reference: PMID:8302340
        supports: SUPPORT
        snippet: &#34;Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis.&#34;
        explanation: Trial of riluzole, an antiglutamate agent, supports role of glutamate excitotoxicity in ALS pathogenesis.
  - name: Oxidative Stress
    description: &gt;
      Motor neurons are particularly vulnerable to oxidative damage due to high metabolic
      demands. Mutations in SOD1, which encodes superoxide dismutase 1, lead to misfolded
      protein aggregation and increased oxidative stress contributing to neuronal death.
    biological_processes:
      - preferred_term: response to oxidative stress
        term:
          id: GO:0006979
          label: response to oxidative stress
    evidence:
      - reference: PMID:8446170
        supports: SUPPORT
        snippet: &#34;a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion&#34;
        explanation: Discovery of SOD1 mutations in familial ALS implicates oxidative stress in disease pathogenesis.
  - name: Neuroinflammation
    description: &gt;
      Activated microglia and astrocytes contribute to motor neuron death through the release
      of pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic factors.
      This non-cell-autonomous mechanism amplifies neurodegeneration.
    cell_types:
      - preferred_term: microglial cell
        term:
          id: CL:0000129
          label: microglial cell
      - preferred_term: astrocyte
        term:
          id: CL:0000127
          label: astrocyte
    evidence:
      - reference: PMID:34440810
        supports: SUPPORT
        snippet: &#34;In the archetypical neurodegenerative disorder amyotrophic lateral sclerosis (ALS), the recruitment of T-cells is well known&#34;
        explanation: Review confirms immune cell involvement in ALS pathophysiology with T-cell recruitment to affected areas.
  - name: Axonal Transport Dysfunction
    description: &gt;
      Impaired axonal transport leads to accumulation of organelles and proteins in motor
      neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal
      components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
    biological_processes:
      - preferred_term: anterograde axonal transport
        term:
          id: GO:0008089
          label: anterograde axonal transport
  - name: Impaired Autophagy
    description: &gt;
      Defects in autophagy and protein quality control pathways lead to accumulation of
      misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes
      (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
    biological_processes:
      - preferred_term: autophagy
        term:
          id: GO:0006914
          label: autophagy
phenotypes:
  - name: Muscle Weakness
    category: Neuromuscular
    frequency: OBLIGATE
    diagnostic: true
    description: Progressive loss of voluntary muscle strength affecting limbs, trunk, and respiratory muscles.
    phenotype_term:
      preferred_term: Muscle weakness
      term:
        id: HP:0001324
        label: Muscle weakness
    evidence:
      - reference: PMID:31871139
        supports: SUPPORT
        snippet: &#34;motor neuron disease (MND)&#34;
        explanation: Study of motor neuron disease patients confirms muscle weakness as a defining feature.
  - name: Fasciculations
    category: Neuromuscular
    frequency: VERY_FREQUENT
    diagnostic: true
    description: Visible involuntary muscle twitching resulting from spontaneous motor unit discharges.
    phenotype_term:
      preferred_term: Fasciculations
      term:
        id: HP:0002380
        label: Fasciculations
  - name: Spasticity
    category: Neurological
    frequency: VERY_FREQUENT
    description: Increased muscle tone and stiffness due to upper motor neuron involvement.
    phenotype_term:
      preferred_term: Spasticity
      term:
        id: HP:0001257
        label: Spasticity
  - name: Hyperreflexia
    category: Neurological
    frequency: VERY_FREQUENT
    description: Exaggerated deep tendon reflexes indicating upper motor neuron dysfunction.
    phenotype_term:
      preferred_term: Hyperreflexia
      term:
        id: HP:0001347
        label: Hyperreflexia
  - name: Dysarthria
    category: Neurological
    frequency: FREQUENT
    description: Difficulty with speech articulation due to weakness of bulbar muscles.
    phenotype_term:
      preferred_term: Dysarthria
      term:
        id: HP:0001260
        label: Dysarthria
  - name: Dysphagia
    category: Neurological
    frequency: FREQUENT
    description: Difficulty swallowing due to weakness of pharyngeal and esophageal muscles.
    phenotype_term:
      preferred_term: Dysphagia
      term:
        id: HP:0002015
        label: Dysphagia
  - name: Respiratory Insufficiency
    category: Respiratory
    frequency: VERY_FREQUENT
    description: Progressive weakness of diaphragm and intercostal muscles leading to ventilatory failure. This is the most common cause of death in ALS.
    phenotype_term:
      preferred_term: Respiratory insufficiency due to muscle weakness
      term:
        id: HP:0002747
        label: Respiratory insufficiency due to muscle weakness
  - name: Generalized Amyotrophy
    category: Neuromuscular
    frequency: VERY_FREQUENT
    description: Wasting of skeletal muscles due to denervation following motor neuron loss.
    phenotype_term:
      preferred_term: Generalized amyotrophy
      term:
        id: HP:0003700
        label: Generalized amyotrophy
biochemical:
  - name: Neurofilament Light Chain (NfL)
    presence: Elevated
    context: CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value
    notes: Used for diagnosis, prognosis, and monitoring therapeutic response in clinical trials
  - name: Phosphorylated Neurofilament Heavy Chain (pNfH)
    presence: Elevated
    context: CSF and serum biomarker of axonal injury
genetic:
  - name: C9orf72 Repeat Expansion
    association: Causative
    notes: Most common genetic cause of ALS (40% familial, 5-10% sporadic); GGGGCC hexanucleotide repeat expansion
    inheritance:
      - name: Autosomal Dominant
    evidence:
      - reference: PMID:21944778
        supports: SUPPORT
        snippet: &#34;Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%)&#34;
        explanation: Original discovery paper establishing C9orf72 as the most common genetic cause of familial ALS.
  - name: SOD1 Mutations
    association: Causative
    notes: First identified ALS gene; accounts for approximately 20% of familial ALS and 2% of sporadic cases
    inheritance:
      - name: Autosomal Dominant
    evidence:
      - reference: PMID:8446170
        supports: SUPPORT
        snippet: &#34;We identified 11 different SOD1 missense mutations in 13 different FALS families.&#34;
        explanation: Original discovery paper identifying SOD1 mutations as a cause of familial ALS.
  - name: TARDBP Mutations
    association: Causative
    notes: Encodes TDP-43 protein; mutations cause approximately 5% of familial ALS
    inheritance:
      - name: Autosomal Dominant
  - name: FUS Mutations
    association: Causative
    notes: RNA-binding protein; mutations cause approximately 5% of familial ALS
    inheritance:
      - name: Autosomal Dominant
  - name: NEK1 Variants
    association: Susceptibility
    notes: Risk variants found in nearly 3% of ALS cases
    evidence:
      - reference: PMID:27455347
        supports: SUPPORT
        snippet: &#34;In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity.&#34;
        explanation: Large-scale genetic study identifying NEK1 variants as risk factors for ALS.
environmental:
  - name: Heavy Metal Exposure
    notes: Occupational exposure to lead, mercury, and other heavy metals has been associated with increased ALS risk.
  - name: Pesticide Exposure
    notes: Agricultural pesticide exposure has been linked to increased ALS incidence in epidemiological studies.
  - name: Military Service
    notes: Veterans have approximately twice the risk of developing ALS compared to the general population, possibly related to environmental exposures.
  - name: Smoking
    notes: Cigarette smoking is a confirmed risk factor for ALS, particularly in women.
treatments:
  - name: Riluzole
    description: &gt;
      Glutamate antagonist that modestly extends survival by 2-3 months. It is the first
      FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:8302340
        supports: SUPPORT
        snippet: &#34;The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset.&#34;
        explanation: Landmark trial demonstrating riluzole&#39;s survival benefit in ALS patients.
  - name: Edaravone
    description: &gt;
      Antioxidant that may slow functional decline in a subset of ALS patients. It reduces
      oxidative stress and has shown benefit in early-stage patients.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:28522181
        supports: SUPPORT
        snippet: &#34;Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo.&#34;
        explanation: Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients.
  - name: Tofersen
    description: &gt;
      Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein
      production, targeting the underlying genetic cause in this subset of patients.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:32640130
        supports: SUPPORT
        snippet: &#34;In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.&#34;
        explanation: Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients.
  - name: Non-invasive Ventilation
    description: &gt;
      Respiratory support using BiPAP or similar devices to assist breathing as respiratory
      muscles weaken. This improves quality of life and extends survival.
    treatment_term:
      preferred_term: noninvasive ventilation
      term:
        id: MAXO:0000506
        label: noninvasive ventilation
  - name: Physical Therapy
    description: &gt;
      Range of motion exercises and adaptive strategies to maintain function and prevent
      complications such as contractures.
    treatment_term:
      preferred_term: physical therapy
      term:
        id: MAXO:0000011
        label: physical therapy
  - name: Speech Therapy
    description: &gt;
      Techniques to optimize communication and swallowing safety, including augmentative
      and alternative communication devices.
  - name: Percutaneous Endoscopic Gastrostomy
    description: &gt;
      Feeding tube placement to maintain nutrition when swallowing becomes unsafe or
      inadequate due to bulbar involvement.
  - name: Multidisciplinary Care
    description: &gt;
      Coordinated care from neurologists, pulmonologists, physical therapists, occupational
      therapists, speech therapists, nutritionists, and palliative care specialists extends
      survival and improves quality of life.
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Amyotrophic_Lateral_Sclerosis.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>